After spinal cord injury (SCi), re-establishing functional circuitry in the damaged central nervous system (CNS) faces multiple challenges including lost tissue volume, insufficient intrinsic growth capacity of adult neurons, and the inhibitory environment in the damaged CNS. Several treatment strategies have been developed over the past three decades, but successful restoration of sensory and motor functions will probably require a combination of approaches to address different aspects of the problem. Degradation of the chondroitin sulfate proteoglycans with the chondroitinase ABC (ChABC) enzyme removes a regeneration barrier from the glial scar and increases plasticity in the CNS by removing perineuronal nets. its mechanism of action does not clash or overlap with most of the other treatment strategies, making ChABC an attractive candidate as a combinational partner with other methods. in this article, we review studies in rat SCi models using ChABC combined with other treatments including cell implantation, growth factors, myelin-inhibitory molecule blockers, and ion channel expression. We discuss possible ways to optimize treatment protocols for future combinational studies. To date, combinational therapies with ChABC have shown synergistic effects with several other strategies in enhancing functional recovery after SCi. These combinatorial approaches can now be developed for clinical application.
Introduction
Spinal cord injury (SCi) patients are usually left disabled for life. The two primary causes of SCi are vehicle accidents and falling from heights. Along with the rapid economic growth in China, the rate of SCi occurrence in Beijing has rapidly increased 10 times from 6.8 per million in the 1980s to 60.6 per million in 2002 [1] .
Following SCi, the challenge of restoring central nervous system (CNS) function faces difficulties in multiple areas. Research in the past three decades has provided several potential solutions by addressing different aspects of the problem. The strategies developed have included cell implantation, neurotrophin supplementation, and treatments to increase CNS plasticity. However, due to the complexity of the injured spinal cord, a single-treatment approach will probably not be sufficient to restore full functionality. in this review, we focus on studies of treatment with chondroitinase ABC (ChABC) combined with cell implantation, neurotrophic factors, neuroprotective agents, and myelin inhibitor antibodies. We first describe the effect and mechanism of ChABC treatment alone, and the viral vector delivery methods. Then we focus on combinational studies, especially the problems arising from the variability in SCi lesion models and their anatomical and behavioral readouts. Furthermore, in order to make clinically-relevant treatment designs, rehabilitation must be incorporated into the combination paradigm. in the last section, we discuss the topics of combination of rehabilitation with ChABC, and the possibility of using a consistent model for future combinational treatment experimental design. with diverse functional roles. After lesions, CSPGs are upregulated several-fold, peaking at between 10 to 14 days post-lesion [2] . Together with activated glial cells, the CSPGs form a dense layer of glial scar inhibitory to axon growth, and much of this inhibition is due to the activity of the glycosaminoglycan (GAG) chains [3] . in addition, CSPGs are major components of the perineuronal nets (PNNs), which are dense ECM structures that form around many neuronal cell bodies and dendrites late in development [4, 5] . in the spinal cord, PNNs surround ~30% of motoneurons in the ventral horn, 50% of large interneurons in the intermediate grey, and 20% of neurons in the dorsal horn [4] , while in the brain they are particularly associated with inhibitory GABAergic interneurons. The PNNs in the visual cortex form in the second week of postnatal development, which coincides with closure of the critical period for visual functions [6] . Formation of these structures and the turning off of plasticity are triggered by impulse activity in neurons.
Treatment with ChABC removes PNNs and reopens a window of CNS plasticity by promoting axon sprouting and the formation of new connections [7] .
ChABC is a bacterial enzyme isolated from Proteus vulgaris [8] . it degrades CSPGs by cleaving the GAG chains into soluble disaccharides or tetrasaccharides, and leaves behind the core protein. This enzymatic digestion results in the release of bound growth factors from chondroitin sulfate GAG chains [9] , and reduction of the glial scar neoepitopeinduced immune response [10] . Also, one of the digestion products, the chondroitin sulfate E-disaccharide, is growthpromoting [11] . The enzyme remains active in vivo for 10 days after injection. in injured spinal cord, intraspinal injection of ChABC 1 mm above and 1 mm below the lesion causes extensive digestion by ChABC covering >5 mm around the lesion site rostro-caudally and 1.5 mm dorso-ventrally [12] .
ChABC has been shown in many in vitro and in vivo models to be an effective treatment for improving axonal regeneration and sprouting, and for promoting functional recovery in acute and chronic SCi in various animal models [13] [14] [15] [16] [17] . in animal experiments, ChABC treatment allows some axons to regenerate through the lesion, and leads to an increased sprouting response in both lesioned and spared systems after SCi [18] . ChABC also digests the PNNs [19] , and opens a window of plasticity which allows effective acquisition of motor skills with rehabilitation [12, 16] .
importantly, none of the sprouting responses seen after
ChABC treatment have led to increased pain sensitivity.
Viral Vector-mediated ChABC Delivery
Both lentiviral (LV) and adeno-associated virus (AAV)
vector tools have been developed to deliver ChABC into the mammalian CNS [20] . [21] . 
Schwann Cells, OECs and ChABC
First, in an in vitro model with Schwann cell/astrocyte coculture, degradation or inhibition of CSPGs by ChABC or xylosyltransferase-1, a DNA enzyme against GAGchain-initiating enzyme, allowed mixing of the two cell types [22] , and indicated that ChABC treatment improves the as locomotor recovery compared to control or graft alone [21] .
This finding was reproduced and additional histological investigation with retrograde tracing showed that axons regenerate across the cell bridge into the caudal spinal cord [23] . Bladder function was also studied in a thoracic transection model, using a similar treatment with Schwann cells, oECs and ChABC [24] . in the combined-treatment group, increased bladder size and decreased amount of disorganized smooth muscle fibers and collagen deposit were found in comparison to the control group.
Neurotrophins, Neural Progenitor Cells, and ChABC
in a clip-compression SCi model, a triple-combination study was performed using implanted neural precursor cells, ChABC, and a cocktail of epidermal growth factor, fibroblast growth factor, and platelet-derived growth factor [25] . This study showed successful differentiation, migration and integration of neural precursor cells (principally into oligodendrocytes), increased GAP43 levels, and increased plasticity of the corticospinal tract (CST) and serotonergic axons. The Basso, Beattie, and Bresnahan (BBB) score was slightly improved two months after treatment, and a significant improvement in ladder-walking recorded only in the combination group [26] . Sensitivity tests showed that the treatment did not lead to aberrant sensory responses or post-traumatic neuropathic pain in these experiments.
in addition, the combination of NT3 and cell implantation with ChABC improved ascending sensory tract regeneration to the targets in the dorsal column nuclei (DCN) after SCi.
Sensory neurons implanted between the SCi site and DCN two weeks after injury were able to grow in the white matter tract, but unable to enter the DCN. This problem was partially resolved by ChABC or NT3 alone, but the combination significantly increased the number of axons entering the target region in the brain stem [27] .
Neuroprotective/conditioning Agents and ChABC
Another approach combined the inflammation-inducing preparation Zymosan and ChABC. in a dorsal root injury model, introducing the conditioning agent to the ganglia before injury, combined with ChABC-induced modification of CSPGs in the dorsal root entry zone (DREZ), resulted in robust regeneration of sensory axons through the DREZ.
Functional connectivity was confirmed by electrophysiology.
However, the conditioning strategy only worked when applied before, but not after injury [28] . in the same lesion model, the neural regeneration effect of oncomodulin, a Ca 2+ -binding protein was tested in combination with cAMP and ChABC. The combination resulted in increased regeneration of sensory nerves into the DREZ, but the effect was extremely limited compared to Zymosan [29] .
Another approach combined ChABC and clenbuterol, a beta2-adrenoceptor agonist that has neuroprotective effects, conducted by Bai et al. [30] . in adult rats with complete transection at T10, ChABC was applied acutely and clenbuterol was supplied in the drinking water. ChABC treatment decreased both CSPG and collagen deposition and reduced the gap between intact regions. Activated cAMP response element binding protein (CREB) was found in retrograde tracing-labeled neurons, which regenerated axons through the lesion site. Recovery of locomotor function was observed 2 to 3 months after the lesion and was enhanced in the combined group [30] .
ChABC and N-methyl-D-aspartate (NMDA) Receptor Type
Previous work has shown that plasticity in motoneurons is increased in the presence of NT3, and the NMDA receptor reverts to an immature type by expressing the NR2D subunit. in a lateral T8 hemisection SCi model, elevating the spinal levels of NT3 while increasing expression of the NR2D subunit of the NMDA receptor was combined with
ChABC. The most axonal sprouting and best behavioral recovery in the BBB locomotor test was seen in the full combination group, and electrical conductivity across the lesion was only reestablished in rats receiving the combination. This treatment did not cause hypersensitivity in any group [31, 32] .
ChABC and Blocking Myelin Inhibitors
Myelin and myelin debris contain several myelin-associated molecules that inhibit regeneration [33] [34] [35] , among which the Nogo-A N-terminal region (amino-Nogo-A) is one of the most potent inhibitors. inhibition of Nogo-A increases axon plasticity and regeneration and improves functional recovery [36] [37] [38] . in a recent study, the effectiveness of a combination of α-Nogo-A, ChABC and rehabilitation was tested in a cervical dorsal column crush model [39] . The combination treatment applied α-Nogo-A antibody acutely, followed by delayed ChABC treatment starting at 3 weeks after injury, and rehabilitation starting at 4 weeks, to accommodate the requirement that α-Nogo-A be applied acutely, and that rehabilitation be given after the cessation 
Combination of Regenerative Treatments with Rehabilitation
Rehabilitation is an integral part of SCi management;
any potential future interventions will almost certainly have to be compatible with rehabilitation. it is therefore important to study the treatment effects of regenerative treatments in combination with rehabilitation. ChABC opens a window of plasticity and has proven effective when specific rehabilitation is given during the period of drug administration, in both acute and delayed stages and up to one year post-injury in two SCi models [16, 31] .
When combined with other treatments however, the timing between treatments and rehabilitation may influence the functional recovery. For example, α-Nogo-A treatment gives better results when the rehabilitation starts after the treatment period, rather than simultaneously [40, 41] . When combined with ChABC and rehabilitation immediately after the lesion, although significantly increased axonal plasticity occurs, functional recovery is insignificant (unpublished data). instead, when the ChABC is delayed for one week, and rehabilitation is started two weeks after completion of α-Nogo-A treatment, the treatment paradigm has a significant synergistic effect [39] , indicating a significant role of timing in treatment planning.
Discussion and Perspective
After injury, tissue repair in the spinal cord faces challenges quantify limb movements [42, 43] .
However, humans depend heavily on supraspinal input, particularly from the CST for motor control. Animal models which test supraspinal inputs may therefore be more clinically relevant. The CST has been a focus for both axon regeneration, and more recently for behavioral tests.
in rodents, the main function of the CST is skilled paw function, which can provide a high-resolution model. Tests include the skilled paw-reaching staircase task [44] [45] [46] , pasta handling [47] , single-pellet retrieval [48, 49] , ladder walking [50, 51] , skilled walking and swimming [52, 53] .
In vivo combinational studies are major undertakings.
introducing each additional treatment into a combinational paradigm adds an extra parameter, which in theory doubles the number of experimental groups and total number of animals. As a result, the scale of an experiment quickly becomes impractical unless a large group of researchers is involved. in order for the results from these large experiments to be comparable, it is important that standardized protocols for behavioral analysis, histological analysis and data processing are used.
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